Legal & General Group Plc Grows Stake in Immunocore Holdings plc (NASDAQ:IMCR)

Legal & General Group Plc grew its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 17.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 136,875 shares of the company’s stock after purchasing an additional 20,163 shares during the period. Legal & General Group Plc’s holdings in Immunocore were worth $4,038,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in IMCR. China Universal Asset Management Co. Ltd. raised its stake in Immunocore by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock valued at $248,000 after buying an additional 960 shares during the last quarter. NEOS Investment Management LLC increased its holdings in shares of Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after acquiring an additional 1,102 shares in the last quarter. Assetmark Inc. raised its position in shares of Immunocore by 5.3% in the 4th quarter. Assetmark Inc. now owns 32,171 shares of the company’s stock valued at $949,000 after purchasing an additional 1,616 shares during the last quarter. Geode Capital Management LLC boosted its stake in Immunocore by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 35,492 shares of the company’s stock worth $1,047,000 after purchasing an additional 420 shares in the last quarter. Finally, Crossmark Global Holdings Inc. grew its position in Immunocore by 36.7% during the 4th quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company’s stock worth $1,121,000 after purchasing an additional 10,217 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of Immunocore in a report on Wednesday, March 12th. JPMorgan Chase & Co. reduced their target price on Immunocore from $54.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday, April 14th. Needham & Company LLC reiterated a “buy” rating and set a $71.00 price target on shares of Immunocore in a research note on Thursday, April 10th. Morgan Stanley restated an “equal weight” rating and issued a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th. Finally, Mizuho dropped their target price on Immunocore from $38.00 to $33.00 and set a “neutral” rating on the stock in a research report on Monday, April 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $63.73.

Insider Transactions at Immunocore

In other news, Director Bros. Advisors Lp Baker bought 807,338 shares of the stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the purchase, the director now directly owns 2,144,060 shares in the company, valued at $63,721,463.20. The trade was a 60.40 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 10.40% of the company’s stock.

Immunocore Stock Up 0.4 %

Shares of IMCR stock opened at $29.52 on Wednesday. Immunocore Holdings plc has a twelve month low of $23.15 and a twelve month high of $62.74. The stock has a market cap of $1.48 billion, a P/E ratio of -31.07 and a beta of 0.75. The stock has a 50 day moving average of $28.74 and a 200 day moving average of $30.36. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.